Table 1.
Characteristics of AML specimens
| Patient | Age, y | AML FAB subtype | Disease stage | Prior therapy | Antecedent hematologic disorder | Cell source | % blasts | Disease karyotype | Disease genetic analyses | Induction therapy | Disease response to induction |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 71 | M1/2 | Diagnosis | None | None | L-PB | > 98% | 46, XY | FLT3-ITD+,NPM-1+ | FLAG | Refractory |
| 2 | 59 | M1/2 | Diagnosis | Decitabine | CMML | BM | 70% | 46, XY, del7(q32) | N/A | 7+3 | Refractory |
| 3 | 74 | M4 | Diagnosis | Adriamycin, cyclophosphamide, taxotere, and XRT to chest wall for stage III breast cancer | None | BM | 40% | 46, XX t(6;11) (q27;q23) | FLT3-ITD−, NPM-1−, MLL+ | CECA | Refractory |
| 4 | 66 | M5 | Relapse | 7+3, HiDAC, allogeneic PBSCT | None | BM | 60% | 46, XY,del12(p11.2), t(15;21)(q22;q22) | FLT3-ITD+, NPM-1− | CECA | Remission |
| 5 | 66 | M2 | Relapse | 7+3 | None | BM | 50% | 46, XX | FLT3-ITD+, NPM-1+ | CECA | Refractory |
AML indicates acute myelogenous leukemia; FAB, French American British; FLT3-ITD, Flt3 internal tandem duplication; NPM-1, nucleophosmin 1 mutation; MLL, mixed lineage leukemia mutation; CMML, chronic myelomonocytic leukemia; L-PB, leukopheresis of peripheral blood; BM, bone marrow; N/A, not applicable; FLAG, fludarabine, cytarabine, G-CSF; 7+3, cytarabine, idarubicin; CECA, cyclophosphamide, etoposide, carboplatin, cytarabine; HiDAC, high-dose cytarabine; and PBSCT, peripheral blood stem cell transplantation.